1 / 37

Where Are We Going?

Where Are We Going?. William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II. The Perfect Storm. The Field. Key Forces. WORKFORCE. Healthcare. Healthcare. $ 28 Billion spent in 2010 to treat addiction which affects 40 million people Versus

jorryn
Télécharger la présentation

Where Are We Going?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Where Are We Going? William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II

  2. The Perfect Storm

  3. The Field

  4. Key Forces WORKFORCE

  5. Healthcare

  6. Healthcare • $ 28 Billion spent in 2010 to treat addiction which affects 40 million people Versus • $107 Billion to treat heart disease which affects 27 million people

  7. Healthcare Relapse Rates Are Similar for Drug Addiction & Other Chronic Illnesses 100 90 80 70 60 Percent of Patients Who Relapse 50 40 50 to 70% 50 to 70% 40 to 60% 30 30 to 50% 20 10 0 Asthma Hypertension Type I Diabetes Drug Addiction McLellan et al., JAMA, 2000.

  8. Healthcare Parity

  9. Healthcare Estimated U.S. Economic Cost to Society Due to Substance Abuse and Addiction Illegal Drugs - $181 billion/year Alcohol - $185 billion/year Tobacco - $158 billion/year Total - $524 billion/year Source: Surgeon General’s Report, 2004; ONCP, 2004; Harwood, 2000.arwood, 2000. Surgeon General’s Report, 2004; ONDCP, 2004; Harwood, 2000.

  10. Healthcare How Its Funded

  11. Healthcare

  12. Healthcare • More people with 3rd party insurance • Shifts cost and focus: deductibles, reimbursement rates, outcome orientation, primary care physician

  13. Healthcare • Shift from management and administration of block grants to focus on “best practices,” grants, and outcome measurements.

  14. Healthcare

  15. Healthcare

  16. Healthcare

  17. Healthcare

  18. Healthcare

  19. Healthcare • 2 Million people in US dependent/abuse opioids • 18,582 Physicians are certified to prescribe buprenorphine. • 9% of SA facilities are Opioid Treatment Programs (OTP) in 2011 • Individuals receiving buprenorphine prescriptions in 2010 was 800,000 with only 5% coming from treatment programs • Emergency department visits involving buprenorphine increased from 3,161 in 2005 to 30,135 visits in 2010 as availability of the drug increased. Source: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (April 23, 2013). The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville, MD.

  20. Healthcare/Medical Source: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (January 29, 2013). The DAWN Report: Emergency Department Visits Involving Buprenorphine. Rockville, MD.

  21. Clinical Trends

  22. Clinical Trends NIDA’s Principles of Treatment • No single treatment is appropriate for all individuals. • Treatment needs to be readily available. • Treatment must attend to multiple needs of the individual, not just drug use. • Multiple courses of treatment may be required for success. • Remaining in treatment for an adequate period of time is critical for treatment effectiveness.

  23. Clinical Trends NIDA’s Principles of Treatment Behavioral Therapies: • Cognitive Behavioral Therapy • Contingency Management Interventions/Motivational Incentives • Community Reinforcement Approach Plus Vouchers • Motivational Enhancement Therapy • The Matrix Model • 12-Step Facilitation Therapy • Family Behavior Therapy • Behavioral Therapies

  24. Clinical Trends “You can’t do cognitive therapy from a manual any more than you can do surgery from a manual.” -Aaron T. Beck, New York Times

  25. Clinical Trends • 1900s “Being on the wagon” • 1930s “Not drinking alcohol” • 1980 Sober is being totally chemically free • 1990-2000 Relapse is a part of recovery

  26. Clinical Trends Audrey Kishline • 2000 Evidence based practices • Moderate drinking • Fewer drinking days

  27. ASAM Definition of Addiction • Addiction is a primary, chronic disease of brain reward, motivation, memory and related circuitry. Dysfunction in these circuits leads to characteristic biological, psychological, social and spiritual manifestations. This is reflected in an individual pathologically pursuing reward and/or relief by substance use and other behaviors.

  28. ASAM Definition of Addiction • Addiction is characterized by the inability to consistently abstain, impairment in behavioral control, craving, diminished recognition of significant problems with one’s behaviors and a dysfunctional emotional response. Like other chronic diseases, addiction often involves cycles of relapse and remission. Without treatment or engagement in recovery activities, addiction is progressive and can result in disability or death.

  29. What is different about this definition? • The focus in the past has been generally on substances associated with addiction. • The new definition clarifies that addiction isn't about drugs, it’s about brains. • It is not the substance or the quantity or frequency of use that makes them an addict. Addiction is about what happens in the reward circuitry of the brain when exposed to a rewarding substance or behavior.

  30. Clinical Trends More Severe Less Severe The Acute Model Vs. ASAM Levels of Care

  31. Clinical Trends

  32. Concerns About DSM-5 Changes • Would significantly increase the number of people being diagnosed with addiction. • The APA has not allowed enough discussion regarding these changes (secondary gain). • It could create false epidemics and medicalication of everyday behavior. • Possible boundary issues between DSM panel members and the pharmaceutical companies.

  33. Public Perception

  34. Clinical Trends ACCOUNTABILITY COURTS

  35. Clinical Trends USE OF TECHNOLOGY

  36. Implications for Clinicians Peer Recovery Supports WORKFORCE Highly Trained

  37. CONCLUSIONS • Medication Assisted Treatment • Physician Office/Counselor Embedded Treatment • Technology becomes a major tool • Increased qualifications for workforce • Serve More people • Prison/Drug courts may become converted to one payer

More Related